Research and Clinical Trials on Bupropion (Amfebutamone, Wellbutrin, Zyban)

Bupropion (Amfebutamone, Wellbutrin, Zyban) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Bupropion (Amfebutamone, Wellbutrin, Zyban).

• A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects
  Status: Completed, Condition Summary: Healthy Subjects
• Bupropion in Helping Adults Stop Smoking
  Status: Active, not recruiting, Condition Summary: Bladder Cancer; Cancer-Related Problem/Condition; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Leukemia; Liver Cancer; Lung Cancer; Pancreatic Cancer
• Pharmacogenetics, Emotional Reactivity and Smoking
  Status: Recruiting, Condition Summary: Tobacco Use Disorder; Smoking Cessation
• Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity
  Status: Active, not recruiting, Condition Summary: Obesity
• Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
  Status: Recruiting, Condition Summary: Bladder Cancer; Cancer-Related Problem/Condition; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Leukemia; Liver Cancer; Lung Cancer; Pancreatic Cancer
• Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban
  Status: Recruiting, Condition Summary: Insomnia; Nicotine Dependence
• The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior
  Status: Recruiting, Condition Summary: Smoking Lapse Behavior
• Smoking Relapse Prevention in Schizophrenia
  Status: Recruiting, Condition Summary: Schizophrenia; Schizoaffective Disorder; Smokers
• Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence
  Status: Not yet recruiting, Condition Summary: Nicotine Dependence; Nicotine Withdrawal
• A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects
  Status: Recruiting, Condition Summary: Obesity
• Effectiveness of Bupropion in Treating Marijuana Dependent Individuals
  Status: Completed, Condition Summary: Marijuana Abuse; Substance-Related Disorders
• Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke
  Status: Completed, Condition Summary: Tobacco-Use Disorder; Schizophrenia; Psychotic Disorders
• Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
  Status: Recruiting, Condition Summary: Schizophrenia and Disorders With Psychotic Features; Tobacco Use Disorder
• Does Sleep Quality Change After Switch From Wellbutrin SR to Wellbutrin XL in Patients With Major Depressive Disorder?
  Status: Recruiting, Condition Summary: Mood Disorder
• Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia
  Status: Completed, Condition Summary: Schizophrenia; Tobacco Use Disorder

 

Get These Clinical Trials as a Newsfeed

Bupropion:             

Current Research Literature on Bupropion (Amfebutamone, Wellbutrin, Zyban)

Here are abstracts for some of the latest research articles to have appeared on Bupropion (Amfebutamone, Wellbutrin, Zyban):

Smoking cessation in pregnancy.

Expert Opin Drug Saf. 2008 Nov; 7(6): 727-37
Rore C, Brace V, Danielian P, Williams D
BACKGROUND: Pregnant women who continue to smoke expose their developing fetus to a wide range of risks. Assisting these patients to stop smoking can be an important intervention for the health of the baby and the mother. The management of pregnant smokers can be challenging, due to the potential risks of pharmacotherapy. There are a number of options available to the clinician to aid smoking cessation in non pregnant women. These include nicotine replacement therapy (NRT), bupropion, varenicline, and a range of non-drug therapies. OBJECTIVE: To provide guidance to prescribers on the best way to manage smoking cessation in the pregnant patient, reviewing the risks and efficacy of the different approaches. METHODS: An extensive literature search was carried out to find original studies which examined issues surrounding the safety and efficacy of methods of smoking cessation in pregnancy. RESULTS/CONCLUSION: NRT is the agent of choice for smoking cessation in pregnancy as the safety of other therapies in pregnancy have not yet been proved.

Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?

Mol Psychiatry. 2008 Nov 4;
Lee HJ, Rao JS, Chang L, Rapoport SI, Kim HW
Agents effective against mania in bipolar disorder are reported to decrease turnover of arachidonic acid (AA) in phospholipids and expression of calcium-dependent AA-selective cytosolic phospholipase A(2) (cPLA(2)) in rat brain. In contrast, fluoxetine, an antidepressant that is reported to switch bipolar depressed patients to mania, increases cPLA(2) expression and AA turnover in rat brain. We therefore hypothesized that antidepressants that increase switching to mania generally increase cPLA(2) and AA turnover in brain. To test this hypothesis, adult male CDF-344 rats were administered imipramine and bupropion, with reported high and low switching rates, respectively, at daily doses of 10 and 30 mg kg(-1) i.p., respectively, or i.p. saline (control) for 21 days. Frontal cortex expression of different PLA(2) enzymes and AA turnover rates in brain when the rats were unanesthetized were measured. Compared with chronic saline, chronic imipramine but not bupropion significantly increased cortex cPLA(2) mRNA activity, protein and phosphorylation, expression of the cPLA(2) transcription factor, activator protein-2alpha (AP-2alpha) and AA turnover in phospholipids. Protein levels of secretory phospholipase A(2), calcium-independent phospholipase A(2), cyclooxygenase (COX)-1 and COX-2 were unchanged, and prostaglandin E(2) was unaffected. These results, taken with prior data on chronic fluoxetine in rats, suggest that antidepressants that increase the switching tendency of bipolar depressed patients to mania do so by increasing AA recycling and metabolism in brain. Mania in bipolar disorder thus may involve upregulated brain AA metabolism.Molecular Psychiatry advance online publication, 4 November 2008; doi:10.1038/mp.2008.117.

[Restless legs syndrome, periodic limb movements, and psychopharmacology.]

Nervenarzt. 2008 Oct 30;
Cohrs S, Rodenbeck A, Hornyak M, Kunz D
Restless legs syndrome (RLS) and the often associated periodic limb movement disorder in sleep (PLMD) frequently occur in the general population as a primary disorder. In addition to organic disease, secondary forms are caused by psychotropic medication. Several antidepressants, antipsychotics, lithium, and opioid withdrawal have been shown to induce or exacerbate RLS and PLMD, while several antiepileptics used as mood stabilizers and some benzodiazepines demonstrate therapeutic potential for treating RLS/PLMD. Systematic or controlled studies for evaluating these side effects still do not exist. Among the antidepressants at higher risk of inducing this disorder are selective serotonin reuptake inhibitors, venlafaxine, and some tetracyclic antidepressants. Under medication with some tricyclic substances, periodic limb movements were observed more often. For some antidepressants with differing transmitter profiles such as bupropion RLS/PLMD ameliorating effects or at least neutral effects (Trazodon, Nortriptylin) have been described in small studies. In case of continued of or newly occurring insomnia a thorough history should be taken to identify a possible RLS/PLMD as an intolerable side effect of treatment. A change in medications should be considered if clinically feasible. In case of RLS/PLMD occurring in psychotic patients switching the antipsychotic and additionally using a second line medication such as antiepileptics or a benzodiazepine should be considered.

Nichtrauchen, ein Essential für eine gesunde Lunge. Raucherentwöhnung ist die wichtigste Präventionsmassnahme überhaupt.

Pharm Unserer Zeit. 2008 Oct 27; 37(6): 494-499
Schunack W
Rauchen ist das grösste Einzelrisiko in unserem Leben. Aufgrund des extremen gesundheitlichen Risikos des Rauchens ist die Behandlung der Tabakabhängigkeit die wichtigste Präventionsmassnahme überhaupt. Für die Verhaltenstherapie wird nach einem Jahr eine Tabak-Abstinenzrate von ca. 13 % angegeben. Die Abstinenzraten nach einem Jahr betragen für Placebo ca. 8 %, für Nicotinersatztherapie ca. 14 %, für Bupropion ca. 16 % und für Vareniclin ca. 22 %. Damit sind gegenüber Placebo bzw. keiner Medikation die 1-Jahres-Abstinenzraten für Nicotinersatztherapie um das ca. 1,8-fache, für die Behandlung mit Bupropion um das ca. 2-fache und für die Vareniclin-Behandlung um das ca. 2,8-fache erhöht. Durch intensive Beratung des Rauchers können die Abstinenzraten weiter verbessert werden. Alle Neben- und Wechselwirkungen sind vor dem Hintergrund zu sehen, dass Weiterrauchen das alles übertreffende Risiko ist. In Deutschland sterben täglich mindestens 300 Menschen an den Folgen des Rauchens.

[Modern medical support for smoking cessation.]

Internist (Berl). 2008 Oct 24;
Hering T
In view of the high morbidity and mortality associated with tobacco, smoking cessation is one of the most urgent medical challenges. It is effective when psychosocial support is combined with accompanying medication. In view of the associated rate of occurrence of cardiovascular diseases, COPD/emphysema as well as lung cancer, it is highly cost-effective. The nicotine replacement substances Bupropion and Varenicline used in smoking cessation therapies demonstrate a well-documented increase in effectiveness. Their use is not complicated. An increase in the overall cessation success rate by a factor of 2-3 is obtained when using an accompanying course of medication.